List of Excipients in Branded Drug NIMODIPINE

Generic Drugs Containing NIMODIPINE

Company	Ingredient	NDC	Excipient
Heritage Pharmaceuticals Inc	nimodipine	23155-108	FERROSOFERRIC OXIDE
Heritage Pharmaceuticals Inc	nimodipine	23155-108	GELATIN
Heritage Pharmaceuticals Inc	nimodipine	23155-108	GLYCERIN
Heritage Pharmaceuticals Inc	nimodipine	23155-108	HYPROMELLOSES

What are the Most Frequently-Used Excipients in NIMODIPINE?

# Of NDCs	Excipient
2	ALCOHOL
1	BUTYL ALCOHOL
1	FD&C RED NO. 40
1	FD&C YELLOW NO. 6 ALUMINUM LAKE

Nimodipine Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 24, 2026

Nimodipine is an off-patent dihydropyridine calcium-channel blocker with a formulation-led opportunity rather than a molecule-led opportunity. Its low aqueous solubility, high lipophilicity, light sensitivity, and narrow administration requirements create room for differentiated oral, enteral, and modified-release products. The strongest commercial positions are likely to come from improved bioavailability, dose uniformity, tube administration, packaging protection, and hospital-use convenience.

What is the current FDA status of nimodipine?

Nimodipine was approved in the United States as Nimotop capsules for reducing the incidence and severity of neurological deficits associated with subarachnoid hemorrhage. The FDA-approved dosage form is a 30 mg liquid-filled oral capsule. Nimodipine is administered orally or through a nasogastric tube after dilution; intravenous administration is contraindicated because of the risk of severe hypotension and death. [1]

Attribute	Nimodipine status
Active ingredient	Nimodipine
Drug class	Dihydropyridine calcium-channel blocker
Original brand	Nimotop
Original sponsor	Bayer
U.S. dosage form	30 mg liquid-filled capsule
Primary U.S. indication	Reduction of neurological deficits after subarachnoid hemorrhage
FDA approval	1988
Administration	Oral or enteral tube administration
IV use	Contraindicated
Biosimilar pathway	Not applicable
Regulatory category	Small-molecule drug

The principal safety issue is the potential for excessive hypotension. Nimodipine is also subject to a major drug-interaction warning with strong CYP3A4 inhibitors and grapefruit or grapefruit juice. These restrictions affect formulation design, labeling, and hospital medication-use protocols. [1]

When does nimodipine lose exclusivity?

Nimodipine’s original U.S. composition-of-matter and product exclusivity periods expired decades ago. The current commercial issue is generic competition and product differentiation, not loss of an active pioneer patent.

No biosimilar competition applies because nimodipine is a chemically synthesized small molecule. Any U.S. generic entrant would use an abbreviated new drug application, subject to bioequivalence and applicable product-quality requirements.

What is the Orange Book status of nimodipine?

The original Nimotop product is not the practical source of current U.S. market exclusivity. Orange Book listings and marketing status should be assessed by reference to the specific NDA, strength, dosage form, and applicant because discontinued brand status and current generic marketing status can differ. The key commercial conclusion is that nimodipine does not have a meaningful remaining U.S. exclusivity barrier comparable to a recently approved drug. [2]

Are there Paragraph IV challenges for nimodipine?

Paragraph IV litigation is unlikely to be a material barrier for a new nimodipine capsule or oral solution unless a current Orange Book-listed formulation or method-of-use patent is identified. The original drug is genericized, and the commercial value of any newly filed patent would depend on whether it protects a clinically meaningful formulation rather than an easily designed-around excipient combination.

For a new applicant, the more relevant regulatory risks are:

• Failure to demonstrate bioequivalence against the reference product.
• Inadequate control of content uniformity in a low-dose, poorly soluble formulation.
• Insufficient stability under light and temperature stress.
• Incomplete compatibility data for nasogastric administration.
• A formulation that changes exposure enough to create hypotension risk.

What excipient properties are required for nimodipine?

Nimodipine has very low water solubility and high lipophilicity. A conventional aqueous tablet or capsule is unlikely to provide reliable performance without particle-size control, wetting enhancement, amorphous dispersion, lipid solubilization, or another enabling technology. [3]

The excipient strategy should address five product attributes:

1. Solubilization of the active ingredient.
2. Maintenance of a stable supersaturated or dissolved state after administration.
3. Protection from light and oxidation.
4. Reproducible dose delivery.
5. Compatibility with oral and enteral administration.

Which excipient systems are suitable for nimodipine?

Formulation objective	Excipient classes	Commercial relevance
Lipid solubilization	Medium-chain triglycerides, long-chain lipids, mono- and diglycerides	Closest to the existing liquid-filled capsule model
Surfactant-assisted dispersion	Polysorbates, polyoxyl castor oils, poloxamers, sucrose esters	Improves wetting and dispersion; requires safety and precipitation control
Cosolvent systems	Ethanol, polyethylene glycol, propylene glycol	Useful in liquids and softgels, but dose and tolerability limits apply
Solid dispersion	Povidone, copovidone, hypromellose, hypromellose acetate succinate	Supports supersaturation and dissolution enhancement
Cyclodextrin complexation	Hydroxypropyl-beta-cyclodextrin, sulfobutyl ether-beta-cyclodextrin	More relevant to liquid or parenteral-style development, with cost and dose-burden concerns
Nanoparticle systems	Stabilized drug nanoparticles with polymeric or surfactant stabilizers	Can support oral suspensions and lower-dose products
Enteral suspension	Cellulosic suspending agents, wetting agents, buffers	Potential hospital and tube-administration opportunity
Antioxidant and protection system	Tocopherols, ascorbyl derivatives, chelators, light-protective packaging	Supports shelf life in lipid or liquid systems

The final excipient selection must be based on the FDA Inactive Ingredient Database, route-specific precedent, permitted daily exposure, and product-specific toxicology. [4]

What formulations are protected by nimodipine patents?

The original nimodipine patent estate is historical and does not provide a durable barrier to current generic development. Future protection would more likely arise from formulation, process, packaging, or method-of-use claims.

Potentially patentable areas include:

• A specific self-emulsifying drug-delivery system.
• A defined lipid and surfactant ratio that improves exposure.
• A stable amorphous nimodipine dispersion.
• A nanoparticle formulation with a specified particle-size distribution.
• A tube-compatible liquid formulation with validated dose recovery.
• A light-resistant capsule and container system.
• A modified-release product that reduces peak plasma concentration.
• A method for treating subarachnoid hemorrhage with a defined exposure profile.

Patent strength would depend on comparative data. A claim covering nimodipine with a routine solubilizer is vulnerable to obviousness and enablement attacks. A stronger patent would connect a narrowly defined composition to unexpected pharmacokinetic, stability, or clinical performance.

How strong is the patent estate for nimodipine?

The legacy estate is weak as a barrier to generic entry because the original active-ingredient protection and regulatory exclusivity have expired. A new formulation estate could be moderate if it demonstrates:

• A substantial increase in dissolution or exposure.
• Lower interpatient variability.
• Improved tube-delivery recovery.
• Longer stability at controlled room temperature.
• Reduced light degradation.
• Lower peak concentration with maintained therapeutic exposure.
• A clinically relevant reduction in hypotension or dosing errors.

Broad excipient claims without comparative performance data would have limited defensive value.

What commercial opportunities exist for nimodipine excipients?

1. Improved softgel capsules

The most direct opportunity is a next-generation liquid-filled softgel using a lipid or self-emulsifying system. The product could target improved dissolution, lower food-effect variability, and better stability.

The commercial challenge is differentiation. A formulation that is merely easier to manufacture may not justify a new drug application or premium pricing. The value proposition must be tied to a measurable clinical or operational benefit.

2. Oral liquid for enteral-tube administration

Nimodipine is used in patients who may be unable to swallow capsules after subarachnoid hemorrhage. A ready-to-use or concentrated oral suspension could reduce manipulation of capsules and improve dose recovery through feeding tubes.

A viable product would need data on:

• Homogeneity during the dosing interval.
• Tube compatibility.
• Recovery after flushing.
• Adsorption to tubing materials.
• Stability after opening.
• Dose accuracy after shaking.
• Compatibility with common enteral feeds.

This is one of the clearest unmet formulation needs because administration errors can occur when liquid-filled capsules are punctured or otherwise manipulated for tube delivery.

3. Solid dispersion capsules or tablets

A solid dispersion could reduce dependence on liquid-filled technology and simplify high-volume manufacturing. Suitable polymers may include povidone, copovidone, hypromellose, and hypromellose-based enteric polymers.

The main technical risk is recrystallization. A formulation that initially produces rapid dissolution may lose performance during storage as nimodipine returns to its crystalline state. Moisture uptake and temperature cycling should be included in development studies.

4. Nanocrystal or nanosuspension products

Nanosizing can increase surface area and improve dissolution without requiring a large excipient load. An oral nanosuspension could support a liquid product, while a dried nanoparticle system could be filled into capsules.

The main barriers are:

• Aggregation during storage.
• Ostwald ripening.
• High-pressure homogenization or milling cost.
• Need for robust particle-size controls.
• Potentially difficult scale-up.
• Limited commercial premium for a product with the same indication.

5. Modified-release nimodipine

A modified-release product could reduce peak-related hypotension and simplify dosing. The clinical rationale is plausible, but the regulatory burden is higher than for an immediate-release generic.

A modified-release program would require pharmacokinetic characterization across fed and fasted states, assessment of dose dumping, and clinical justification for the revised exposure profile. A new delivery system may obtain formulation patents, but it would also face more complex bioequivalence requirements.

How does nimodipine compare with competing calcium-channel blockers?

Nimodipine is differentiated by its use after subarachnoid hemorrhage rather than by broad hypertension or angina volume. Amlodipine, nifedipine, felodipine, and nicardipine have larger cardiovascular markets and broader generic competition.

Drug	Principal use	Formulation opportunity	Commercial assessment
Nimodipine	Subarachnoid hemorrhage	Enteral liquid, softgel, dissolution enhancement	Niche hospital and specialty opportunity
Amlodipine	Hypertension, angina	Low-cost tablets, fixed-dose combinations	Large but highly commoditized
Nifedipine	Hypertension, angina	Extended-release systems	Stronger modified-release precedent
Nicardipine	Hypertension, acute care	Injectable and oral products	Hospital-focused competition
Felodipine	Hypertension	Extended-release tablets	Smaller market with established generic products

Nimodipine’s smaller market can support a focused product if the formulation solves a hospital workflow problem. It is less attractive for a conventional commodity tablet strategy.

What manufacturing and intellectual-property barriers affect nimodipine?

Manufacturing barriers are more important than active-ingredient patent barriers.

Liquid-filled softgels

Softgel manufacturing requires control of fill viscosity, shell compatibility, seam integrity, fill weight, and long-term migration between the fill and gelatin shell. Lipid oxidation can affect appearance, potency, and impurities.

Amorphous dispersions

Hot-melt extrusion and spray drying can improve dissolution but require control of residual solvent, polymer miscibility, moisture, and recrystallization. Scale-up data are essential for patent defensibility and regulatory acceptance.

Nanoparticles

Particle-size distribution, stabilizer selection, milling media, and microbial control determine product consistency. A process patent may be stronger than a broad composition patent if the manufacturing route produces a reproducible clinical advantage.

Packaging

Light-protective blister packs, opaque bottles, desiccants, and oxygen-control systems may be central to shelf-life claims. Packaging claims are usually narrower than composition claims but can protect a commercially important presentation.

Which companies are challenging nimodipine exclusivity?

Nimodipine has no active biologic exclusivity and no meaningful remaining pioneer exclusivity in the United States. Generic manufacturers and contract development and manufacturing organizations can compete through abbreviated applications, authorized generics, or formulation improvements.

The likely competitive groups are:

• Established generic capsule manufacturers.
• Hospital-drug suppliers.
• Specialty firms developing enteral products.
• Softgel manufacturers with lipid-formulation capability.
• CDMOs offering spray drying, hot-melt extrusion, or nanomilling.
• Regional pharmaceutical companies in markets where nimodipine remains clinically used.

A new entrant would compete on supply reliability, tube administration, stability, and hospital procurement economics rather than on molecule ownership.

What revenue exposure and launch scenarios exist?

Nimodipine revenue is concentrated in a specialized indication. A plain immediate-release generic is likely to face price competition. A differentiated formulation has greater potential for margin protection but must support a clear regulatory and clinical claim.

Launch scenario	Development burden	Pricing potential	Main risk
Conventional 30 mg capsule	Low to moderate	Low	Rapid generic price erosion
Improved liquid-filled softgel	Moderate	Moderate	Limited clinical differentiation
Enteral-ready oral suspension	Moderate	Moderate to high in hospitals	Tube compatibility and demand concentration
Solid dispersion capsule	Moderate to high	Moderate	Recrystallization and bioequivalence
Nanoparticle suspension	High	High if clinically differentiated	Scale-up and stability
Modified-release product	High	High	Clinical and regulatory complexity

The most credible near-term opportunity is an enteral-compatible oral liquid or improved softgel supported by pharmacokinetic, stability, and administration data. A modified-release product offers greater intellectual-property potential but carries a materially higher development cost.

What is the likely generic launch risk?

For a standard nimodipine capsule, generic launch risk is high because the product is mature and the technical formulation is established. For a protected liquid, nanoparticle, or modified-release product, launch risk shifts from patent expiry to design-around, bioequivalence, and manufacturing feasibility.

A competitor could potentially avoid a formulation patent by changing:

• The lipid phase.
• Surfactant identity.
• Polymer grade.
• Particle-size range.
• Capsule shell composition.
• Manufacturing sequence.
• Packaging configuration.

Patent claims should therefore cover composition, process, dosage form, and clinically supported performance where possible. A single narrow composition patent is unlikely to provide durable market protection.

Key Takeaways

• Nimodipine is a mature small-molecule drug with no biosimilar issue and limited remaining pioneer exclusivity.
• The principal technical problem is poor aqueous solubility combined with the need for reliable oral or enteral dosing.
• Lipid-filled softgels, self-emulsifying systems, solid dispersions, nanosuspensions, and enteral liquids are the main formulation paths.
• The strongest commercial opportunity is a hospital-oriented enteral formulation that improves dose accuracy and tube administration.
• Formulation patents require comparative data showing better dissolution, exposure, stability, or administration performance.
• Conventional generic capsules face high price and launch competition.
• Manufacturing know-how, packaging, and stability control may provide more practical protection than legacy composition patents.
• IV nimodipine is not an acceptable commercial formulation strategy because intravenous administration is contraindicated.
• The U.S. opportunity is specialized, while regional markets may support additional demand where nimodipine remains routinely used after subarachnoid hemorrhage.

FAQs

Is nimodipine a good candidate for a liquid oral formulation?

Yes. Its use in patients with swallowing impairment and the need for nasogastric administration create a practical rationale for a ready-to-use oral liquid, provided the product maintains dose uniformity, stability, and tube recovery.

Which excipient is best for improving nimodipine solubility?

No single excipient is universally optimal. Lipid vehicles, surfactants, cosolvents, polymers, and nanocrystal stabilizers should be screened against exposure, precipitation, stability, tolerability, and regulatory precedent.

Can nimodipine be reformulated as an injectable product?

An injectable product would face major safety and regulatory barriers. The approved labeling contraindicates intravenous administration because of severe hypotension risk. [1]

Does nimodipine have meaningful formulation-patent potential?

Yes, but protection would require a narrowly defined formulation supported by unexpected performance. A routine combination of nimodipine with a conventional solubilizer would likely provide weaker patent protection.

What is the best commercial entry strategy for a new nimodipine manufacturer?

A differentiated enteral liquid, tube-compatible suspension, or bioavailability-enhanced softgel is more defensible than a standard immediate-release capsule. The product should be supported by hospital-use data and a clear administration or stability advantage.

References

1. U.S. Food and Drug Administration. (2020). Nimodipine prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. National Library of Medicine. (2024). Nimodipine compound summary. PubChem.

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.